Evidence map›Paper›PMID 35214115›Full record

ReviewPharmaceutics2022

Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update.

Anroop B Nair, Sunil Kumar, Pooja Dalal, Chahat Nagpal, Sweta Dalal, Rekha Rao, Nagaraja Sreeharsha, Shery Jacob

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Novel drug delivery systems in topical treatment of atopic dermatitis.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Anroop B NairDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Hofuf 31982, Al-Ahsa, Saudi Arabia.ORCID 0000-0003-2850-8669
Sunil KumarDepartment of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India.ORCID 0000-0002-4466-3215
Pooja DalalDepartment of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India.ORCID 0000-0003-1077-6817
Chahat NagpalDepartment of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India.ORCID 0000-0001-9775-0729
Sweta DalalDepartment of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India.ORCID 0000-0002-0384-1361
Rekha RaoDepartment of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India.
Nagaraja SreeharshaDepartment of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Hofuf 31982, Al-Ahsa, Saudi Arabia.ORCID 0000-0002-2058-255X
Shery JacobDepartment of Pharmaceutical Sciences, College of Pharmacy, Gulf Medical University, Ajman 4184, United Arab Emirates.ORCID 0000-0003-1851-6673
Guru Jambheshwar University of Science and Technology · INKing Faisal University · SAGulf Medical University · AE

Funding

Deanship of Scientific Research, King Faisal University, Saudi Arabia NA 000112
6 · The paper itself

Abstract

Dermal disorders such as psoriasis and eczema are associated with modifications in the chemical and molecular composition of the skin. Clobetasol propionate (CP), a superpotent topical glucocorticoid, is widely used for the therapeutic management of various skin conditions, owing to its strong anti-inflammatory, antipruritic, vasoconstrictive, and antiproliferative activities. Safety studies demonstrated that CP is safer for a shorter period, however, with prolonged application, it shows secondary side effects such as photosensitivity, Cushing-like syndrome, allergic contact dermatitis, osteonecrosis, hypopigmentation, steroid acne, and skin atrophy. Therefore, the US FDA (United States Food and Drug Administration) has restricted the usage of CP to not more than 15 days. Research scientists addressed its several formulations and drug delivery issues, such as low water solubility, less stability, photodegradation, and poor absorption, by incorporating them into novel nanobased delivery platforms. With the utilization of these technologies, these drawbacks of CP have been resolved to a large extent to reestablish this moiety. This article explores the physicochemical properties and mechanism of action of CP. Additionally, an attempt has been made to discover and highlight the possible features of the novel nanosystems, including nanoemulsions, nanosponges, solid lipid nanoparticles, nanostructured lipid carriers, and nanogels, reported for CP. The stability and safety concerns of CP, along with its commercial status, are also discussed.

Indexed as

cell line studiesdermal deliveryin vivo studiesnanoformulationssafety concernsstability concerns

Identifiers

PMID35214115
PMCPMC8877216
OpenAlexW4211009716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.